SCYNEXIS (SCYX) vs Shuttle Pharmaceuticals (SHPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 35.6% versus a loss of 88.8%. SCYNEXIS is the larger company by market cap ($40.6 million vs $25.4 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCYX | SHPH |
|---|---|---|
| Share price | $4.08 | $5.33 |
| Market cap | $40.59M | $25.40M |
| 1-day change | -3.32% | -4.05% |
| YTD return | -19.30% | -70.39% |
| 1-year return | -35.61% | -88.80% |
| 5-year return | -90.84% | — |
| EPS (TTM) | $-0.89 | $-16.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.12 | $55.90 |
| 52-week low | $3.53 | $2.58 |
| Distance from 52-week high | -55.26% | -90.47% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +790.44% | — |
| Average volume | 279.10K | 1.36M |
| Shares outstanding | 9.95M | 4.76M |
| Employees | 18 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed SHPH by 53.2 percentage points over the past year.
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
SCYX vs SHPH FAQ
Which is bigger, SCYNEXIS or Shuttle Pharmaceuticals?
SCYNEXIS (SCYX) is larger, with a market capitalization of $40.59M compared with $25.40M for Shuttle Pharmaceuticals (SHPH).
Which stock has performed better over the past year, SCYX or SHPH?
SCYX returned -35.61% over the past 12 months, compared with -88.80% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are SCYNEXIS and Shuttle Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.